- Joined
- Apr 9, 2021
- Messages
- 1,717
Ask them what they think then about the data showing no detectable PR binding from the Houtman mammalian reporter bioassay (Stevenson, at least, will certainly be familiar with this data).Yes this is called cross receptor activation.. think about it this way, Anadrole is a DHT drug it litteraly cant aromatize because its already reduced yet you can get estrogen/progestorene side effects such as gyno from it, i have talked with Dr.Scott stevenson and Dave Crosland about this and they think the same as me its cross receptor activation
It's an interesting open question, from where do oxymetholone's ostensible "gynecomastic" sides arise?
I suspect it's due to one or more of the following:
- a tendency to increase 17-OHP, a "weak" progestin [41]. Note that Camerino [126] cites Junkmann and Suchowsky, 1962 that "showed no gestagenic effect" at therapeutic doses. No direct PR binding (moderately to AR, weakly to ER-alpha (weaker than oxandrolone and stanozolol) & ER-beta in mammalian reporter gene bioassay [28]
- potential for MR agonism?
- potential activation of RAAS?
References:
[41] Patt M, Beck KR, Di Marco T, Jäger MC, González-Ruiz V, Boccard J, Rudaz S, Hartmann RW, Salah M, van Koppen CJ, Grill M, Odermatt A. Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis. Biochem Pharmacol. 2020 Feb;172:113781. doi: 10.1016/j.bcp.2019.113781. Epub 2019 Dec 27.
[126] Camerino, B., & Sciaky, R. (1975). Structure and effects of anabolic steroids. Pharm
acology & Therapeutics. Part B: General and Systematic Pharmacology, 1(2), 233–275. doi:10.1016/0306-039x(75)90007-0
[28] Houtman, C. J., Sterk, S. S., van de Heijning, M. P. M., Brouwer, A., Stephany, R. W., van der Burg, B., & Sonneveld, E. (2009). Detection of anabolic androgenic steroid abuse in doping control using mammalian reporter gene bioassays. Analytica Chimica Acta, 637(1-2), 247–258. doi:10.1016/j.aca.2008.09.037